
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc. is witnessing a significant uptick in Chromium reaction volumes, indicating a strong and resilient market presence despite anticipated pricing pressures. The company is projected to see substantial growth in consumables, potentially increasing 5-19 times per platform by 2027, highlighting a favorable trajectory for revenue generation beyond instrument sales. As the life sciences industry continues to evolve, the integrated solutions offered by 10x Genomics position the company for sustained success in analyzing complex biological systems.
Bears say
10x Genomics Inc. faces a challenging outlook due to a contraction in revenue in 2024, which is compounded by significant pricing pressure and flat to modestly lower sales volumes, with expectations for growth not resuming until 2027. The company's recent earnings report revealed larger-than-anticipated losses, as reflected in an EPS miss and a full-year revenue outlook that fell short of expectations. Furthermore, despite some segment expansion since the stock's peak in 2021, the growth has not matched forecasted levels from analysts, resulting in a decline of over 90% in stock value since that high point.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares